Private Placement

Beale Infrastructure's massive data center breaks ground in Kansas, promising jobs but raising questions about water, transparency, and sustainability.

A new NFC-enabled keychain blends physical nostalgia with digital access, promising indie artists a direct line to fans and their wallets. But can it work?

A new study shows RIVANNA's Accuro XV allows staff with minimal training to get diagnostic images, promising to speed up care and reduce ER wait times.

With its new Orchestra platform, Wetour Robotics is using edge AI to bridge the gap between smart devices, but can the company pull off its ambitious pivot?

Investment firm Malar Group backs wellness startup Attaboy Labs, betting on clinical science over marketing hype in the booming supplement industry.

With patient enrollment accelerating for its novel lung fibrosis drug, LTI-03, Rein Therapeutics signals progress in a field desperate for new options.

Seattle startup CounterX Therapeutics to present its novel overdose prevention drug at a top investor event, signaling new hope in the fentanyl crisis.

A new advisory firm is tackling the opaque world of aesthetic device sales, promising to save providers up to $80,000 on high-ticket equipment.

Scholar Hotels is launching a $5,000 minimum investment platform for its State College properties, tapping into alumni loyalty and a new era of retail investing.

Scottish biotech EnteroBiotix secures major funding to advance its gut therapy for IBS-C, offering new hope for a disease-modifying treatment.

With strategic investments and a new Cannes workshop, Yoshihiro Shimamura is building an integrated media empire to export Japanese culture worldwide.

With financials improving but competition rising, medical device maker Pulmonx faces a critical audience at the BofA healthcare conference in May.

The new AI platform iQ aims to translate complex supply chain threats into quantifiable financial exposure, giving CFOs a new tool for strategic decisions.

A new ultra-short-acting drug for cardiac emergencies is now in US hospitals, offering doctors faster control and broader use across all age groups.

A new FDA-Paradigm Health partnership uses AI to review clinical trial data in real time, aiming to cut drug development costs and approval delays.

A new HHS agenda reopens the door for controversial peptides, just as a wave of next-gen obesity drugs threatens to upend the entire market.

An $850M deal for an Arizona cobalt plant marks a pivotal US-Japan move to secure supply chains for defense, EVs, and advanced tech from rivals.

A new report shows 50% of founders fear AI disruption, while burnout and the timeless challenge of product-market fit continue to plague the startup world.

A new survey reveals Canadian millennials are disciplined savers for their kids' education, but a staggering 'confidence gap' shows the toll of today's economy.

The beverage startup partners with Hershey, betting on the power of nostalgia and the booming health-conscious market with its new candy-flavored teas.